New Studies Highlight Potential Eye Risks Linked to GLP-1 Drugs in Diabetes Management

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic neuropathy (NAION), associated with GLP-1 agonist drugs like semaglutide and tirzepatide. Despite their benefits for diabetes and obesity, users should consider risks, especially in individuals with existing risk factors.

Two new studies have revealed potential eye health risks linked to the use of GLP-1 drugs, commonly prescribed for diabetes management and weight loss. These medications, including semaglutide and tirzepatide, could increase the likelihood of developing serious eye conditions such as non-arteritic anterior ischaemic optic neuropathy (NAION), also known as an eye stroke.

The studies examined medical records of over 340,000 people with type 2 diabetes in the United States and found a slightly elevated risk of NAION in patients taking these drugs, contrary to previous assumptions. One study indicated a modest increase in NAION cases, while the other did not find a significant link. However, both studies noted a rise in diabetic retinopathy cases among users.

As GLP-1 drugs continue to offer significant benefits in managing diabetes and combating obesity, healthcare professionals urge a balanced consideration of the associated risks. Regular eye examinations and informed decision-making are vital, particularly for patients with existing risk factors such as diabetes, high blood pressure, or anatomical vulnerabilities in the optic nerve.